Inflaming depression

Journal of Psychiatry and Neuroscience

Volumn 36, Issue 5, 2011, Pages 291-293

  Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CELECOXIB; ETANERCEPT; FLUOXETINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANXIETY DISORDER; CYTOKINE PRODUCTION; DEPRESSION; EDITORIAL; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATION; LIFESTYLE; MOOD DISORDER; PATHOPHYSIOLOGY; PSORIASIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SCHIZOPHRENIA;

EID: 80052059600     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110071     Document Type: Editorial

References (38)

1. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008;85:1-74.
2. Dantzer R, O'Connor JC, Lawson MA, et al. Inflammationassociated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011;36:426-36.
3. Maes M, Leonard BE, Myint AM, et al. The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702-21.
4. Shelton RC, Miller AH. Inflammation in depression: Is adiposity a cause? Dialogues Clin Neurosci 2011;13:41-53.
5. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-52.
6. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.
7. Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-73.
8. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon alpha. N Engl J Med 2001;344:961-6.
9. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23: 417-22.
10. Kubera M, Grygier B, Arteta B, et al. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep 2009;61:1113-26.
11. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009;9:429-39.
12. Kamm K, Vanderkolk W, Lawrence C, et al. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma 2006;60:152-7.
13. Zhu Y, Saito K, Murakami Y, et al. Early increase in mRNA levelsof pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia. Neurosci Lett 2006; 393: 122-6.
14. Nguyen KT, Deak T, Owens SM, et al. Exposure to acute stress induces brain interleukin-1β protein in the rat. J Neurosci 1998;19: 2799-805.
15. Pascoe MC, Crewther SG, Carey LM, et al. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke 2011;6:128-35.
16. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998;56:149-71.
17. Craft TK, DeVries AC. Role of IL-1 in poststroke depressive-like behavior in mice. Biol Psychiatry 2006;60:812-8.
18. Spalletta G, Bossù P, Ciaramella A, et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11: 984-91.
19. Anisman H, Poulter MO, Gandhi R, et al. Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J Neuroimmunol 2007;186:45-53.
20. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
21. Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Higher plasma nterleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:722-6.
22. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473-6.
23. Prather AA, Rabinovitz M, Pollock BG, et al. Cytokine-induced depression during IFN-α treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009;23:1109-16.
24. Merali Z, Brennan K, Brau P, et al. Dissociating anorexia and anhedonia elicited by interleukin-1β: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology (Berl) 2003;165:413-8.
25. Maier SF, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 1995; 695:279-82.
26. Shintani F, Nakaki T, Kanba S, et al. Involvement of interleukin-1 in immobilization stressinduced increase in plasma adrenocor ticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995;15:1961-70.
27. Kekow J, Moots R, Khandker R, et al. Improvements in patient- reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology 2011; 50: 401-9.
28. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
29. Soczynska JK, Kennedy SH, Goldstein BI, et al. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009;30:497-521.
30. De La Garza R, Asnis GM, Pedrosa E, et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:781-92.
31. Fahey B, Hickey B, Kelleher D, et al. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behav Brain Res 2007;182:80-7.
32. Myint AM, O'Mahony S, Kubera M, et al. Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. J Psychopharmacol 2007;21:843-50.
33. Smith AK, Simon JS, Gustafson EL, et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry 2011 June 21. doi: 10.1038/mp.2011.67. [Epub ahead of print]
34. Müller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008;14:1452-65.
35. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26:607-11.
36. Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci 2010;35:219-20.
37. Catena-Dell'Osso M, Bellantuono C, Consoli G, et al. Inflammatory and neurodegenerative pathways in depression: A new avenue for antidepressant development? Curr Med Chem 2011;18:245-55.
38. Hayley S. Toward an anti-inflammatory strategy for depression. Front Behav Neurosci 2011;5:19.